Agency Business briefs

Share this article:
WPP announced plans to acquire Marketing Direct, Inc. through Wunderman's KBM Group. Marketing Direct offers direct and interactive marketing services for healthcare and insurance providers, and boasts 64 employees.

Publicis Healthcare Communications Group acquired Digital District, a Dusseldorf, Germany-based digital healthcare and communications strategy shop. The agency will be folded into Publicis Healthware International, the network's global digital communications arm. Aleksandar Stojanovic will continue to lead the shop.

Creston PLC, a UK-based communications company, announced plans to acquire healthcare PR shop Cooney Waters and its healthcare advocacy subsidiary Alembic Health Communications for $30.8 million in cash.  

Topin & Associates promoted Prill Kozel (below) to creative director and Tanja Noren to account director. The Chicago indie shop also announced the hires of Steven Rupuer as account exec and Erin Schwarz as copywriter.

Vox Medica named Karen Beckert SVP. Beckert joins from Ogilvy & Mather, where she was senior partner and executive group director.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?